Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00396370 · ClinicalTrials.gov registry record · Phase 1
BCG Vaccination Delivered Intradermally, Orally and by Combined Routes
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT00396370 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 69 participants.
The verdict
NCT00396370, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This study will assess the safety of a Bacillus Calmette-Guérin (BCG) vaccine against tuberculosis (TB) and will evaluate if giving the vaccine by mouth, injection, or by both methods produces greater results. BCG vaccine and/or placebo (substance containing no medication) will be given by mouth and/or by injection into the skin. This study, conducted at Saint Louis University, will enroll 60 (up to 80) healthy volunteers, 18-40 years old, who are negative for a TB test (QuantiFERON®-Gold) and human immunodeficiency virus (HIV). Study procedures will include a physical exam; review of TB exposure history and medical history; collection of multiple samples of blood, urine, stool, tears, and nose fluid; and skin and blood tests for TB. Volunteers may participate for about 24 months.
Interventions
- OTHER Placebo
- BIOLOGICAL BCG strain Connaught
- BIOLOGICAL BCG strain Danish
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2008-12-02 |
| Est. Completion | 2012-07-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00396370
The ClinicalTrials.gov registry entry for NCT00396370 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00396370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00396370 about?
NCT00396370 is a clinical study titled "BCG Vaccination Delivered Intradermally, Orally and by Combined Routes". This study will assess the safety of a Bacillus Calmette-Guérin (BCG) vaccine against tuberculosis (TB) and will evaluate if giving the vaccine by mouth, injection, or by both methods produces greater results. BCG vaccine and/or placebo (substance containing no medication) will be given by mouth and...
What is the current status of trial NCT00396370?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2008-12-02. Estimated completion is 2012-07-23.
What interventions are being tested in trial NCT00396370?
The interventions under investigation include: Placebo (OTHER), BCG strain Connaught (BIOLOGICAL), BCG strain Danish (BIOLOGICAL).
Who is sponsoring clinical trial NCT00396370?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.